Spectrofluorometric Analysis of New-Generation Antidepressant Drugs in Pharmaceutical Formulations, Human Urine, and Plasma Samples

Table 7

Recovery studies of analytes in urine and plasma by proposed method.

Amount added (ng/μL)	Urine		Plasma
	Found	Recovery	Found	Recovery
	(ng/μL) ± SD^1	± RSD^2 (%)	(ng/μL) ± SD^1	± RSD^2 (%)
SER
10	08.88±0.023	88.80±2.37	08.61±0.062	86.10±2.06
50	48.15±0.029	96.30±4.46	48.56±0.018	97.12±4.80
100	97.02±0.037	97.02±4.86	98.06±0.074	98.06±5.40
PAR
10	08.92±0.075	89.20±2.36	08.92±0.087	89.20±1.50
50	51.27±0.096	102.54±4.33	49.87±0.043	99.74±3.90
100	98.03±0.073	98.03±5.56	98.35±0.184	98.35±6.50
CIT
10	08.45±0.049	85.50±1.65	08.93±0.046	89.30±2.70
50	51.05±0.059	102.1±3.15	48.05±0.039	96.10±4.50
100	98.79±0.042	98.79±4.91	98.65±0.025	98.68±5.30
VLF
10	09.08±0.104	90.80±2.38	08.51±0.134	85.10±1.30
50	48.81±0.073	97.62±4.78	48.32±0.065	96.64±4.04
100	101.87±0.125	100.87±5.80	100.15±0.143	100.15±5.08
FLX
10	10.30±0.145	103.00±1.89	09.22±0.148	92.20±1.80
50	49.75±0.103	99.50±4.72	49.17±0.108	98.34±4.40
100	102.98±0.075	102.98±5.67	101.32±0.059	101.32±5.30

¹Average of six determinations; ²recovery of amount added to the urine and plasma samples (average of six determinations).